Osaka University Graduate School of Medicine

Beth Israel Deaconess Medical Center

<div><p><b>Background: </b>Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of chronic liver disease in the US. Notably, disease prevalence differs greatly by race/ethnicity, with the highest prevalence in those of Hispanic and Asian ancestry, and the lowest prevalence in those of African ancestry. To date, studies have identified common variants associated with MASLD in predominantly European or American populations.

<div><p><b>Background: </b>Studies on incident liver and cardiovascular outcomes in lean (body mass index: BMI &lt;25 kg/m², or &lt;23 kg/m² for Asians) vs. non-lean individuals with metabolic dysfunction-associated steatohepatitis (MASH) have reported mixed results. We aimed to compare incident clinical outcomes and mortality between lean and non-lean individuals with compensated MASH cirrhosis in a large national cohort.</p>

<div><p><b>Background:</p> </b><p>Metabolic dysfunction-associated steatohepatitis (MASH) patients who have developed stage F4 fibrosis (cirrhosis) are at risk of hepatic decompensation, hepatocellular carcinoma, liver transplant, cardiovascular events, liver and all-cause mortality. There are currently no approved therapies for non-cirrhotic or cirrhotic MASH.</p>

<div><p><strong>Background</strong>: <span data-contrast="none" xml:lang="EN-US" lang="EN-US" class="TextRun SCXW199784672 BCX0"><span class="NormalTextRun SCXW199784672 BCX0" data-ccp-charstyle="x_x_normaltextrun">Outcomes of adults with ZZ alpha-1-antitrypsin deficiency (AATD) liver disease is variable and unpredictable. There is a lack of prospective data, including on the utility of liver biopsy.

<div><p><b>Background: </b>Providers at community hospitals often seek to transfer hospitalized patients with advanced liver disease to tertiary/quaternary care hospitals for further management due to lack of expertise in caring for these patients. However, it is possible to co-manage such patients at local hospitals by providing virtual consultation by tertiary care hepatologists via inpatient telehepatology (INP-TH) consultation.

<div><p><b>Background: </b>With the ongoing opioid epidemic, hepatitis C virus (HCV) prevalence in women of childbearing potential has increased in North America. As pregnancy may be the only time many women interact with the healthcare system, it presents an opportune time for HCV screening and linkage to care. Poor postpartum follow-up may justify treatment in pregnancy, but there is currently little known about the cascade of care for women of childbearing potential with HCV in pregnancy or postpartum.</p>

<div><p><b>Background: </b>Treatment of CHB with JNJ-3989 and NA &#177; JNJ-6379 has shown profound reductions in serum hepatitis B viral (HBV) markers. The INSIGHT study aims to assess intrahepatic changes in virological and immunological markers with JNJ-3989 based treatment in CHB patients.</p>

<div><p><b>Background: </b>Environmental pollutants are associated with disrupted hepatic metabolism and NAFLD. A pilot study (n=140) presented at AASLD elucidated exposures and metabolic pathways associated with NAFLD severity. To confirm these findings, a larger cross-sectional multi-‘omics study was performed in subjects with NAFLD. </p>